Systemic lupus erythematosus and malignancies: A review article

Rheumatic Disease Clinics of North America

Volumn 40, Issue 3, 2014, Pages 497-506

  Cloutier, Basile Tessier ^a   Clarke, Ann E ^b   Ramsey Goldman, Rosalind ^c   Gordon, Caroline ^d   Hansen, James E ^e   Bernatsky, Sasha ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Epidemiology; Malignancy; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; APRIL PROTEIN; AUTOANTIBODY; AZATHIOPRINE; CELL PENETRATING DNA ANTIBODY; CYCLOPHOSPHAMIDE; DNA ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; FAS ANTIGEN; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ANUS CARCINOMA; APOPTOSIS; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOPHAGY; B LYMPHOCYTE; BREAST CARCINOMA; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CELL IMMORTALIZATION; CELL MIGRATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA REPAIR; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; ENDOMETRIUM CANCER; EPIGENETICS; EPSTEIN BARR VIRUS; ESTROGEN METABOLISM; EVIDENCE BASED MEDICINE; FOLLOW UP; GENE INTERACTION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEAD AND NECK CANCER; HELPER CELL; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNOGLOBULIN GENE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LARGE CELL LYMPHOMA; LUNG CANCER; LYMPHOCYTE FUNCTION; MULTIPLE MYELOMA; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PATHOPHYSIOLOGY; PATIENT COUNSELING; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTO ONCOGENE; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SMOKING CESSATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIPLE NEGATIVE BREAST CANCER; TUMOR VIRUS; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; VAGINA CARCINOMA; VERRUCA VULGARIS; VIRAL CLEARANCE; VIRUS LOAD; VULVA CARCINOMA; WART VIRUS; COMORBIDITY; EARLY DIAGNOSIS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEOPLASMS; RESEARCH;

COMORBIDITY; EARLY DETECTION OF CANCER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEOPLASMS; RESEARCH; RISK FACTORS;

EID: 84904391925     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.04.005     Document Type: Review

References (71)

1. Pons-Estel G.J., Alarcón G.S., Scofield L., et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010, 39(4):257-268.
2. Trager J., Ward M.M. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001, 13(5):345-351.
3. Zintzaras E., Voulgarelis M., Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005, 165(20):2337-2344.
4. Lofstrom B., Backlin C., Pettersson T., et al. Expression of APRIL in diffuse large Bcell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. JRheumatol 2011, 38(9):1891-1897.
5. Kassan S.S., Thomas T.L., Moutsopoulos H.M., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978, 89(6):888-892.
6. Bernatsky S., Boivin J.F., Joseph L., et al. Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity. JRheumatol 2002, 29(12):2551-2554.
7. Bernatsky S., Ramsey-Goldman R., Labrecque J., et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. JAutoimmun 2013, 42:130-135.
8. Parikh-Patel A., White R.H., Allen M., et al. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008, 19(8):887-894.
9. Bjornadal L., Lofstrom B., Yin L., et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002, 31(2):66-71.
10. Mellemkjaer L., Andersen V., Linet M.S., et al. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40(4):761-768.
11. Bernatsky S., Ramsey-Goldman R., Foulkes W.D., et al. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 2011, 104(9):1478-1481.
12. Bernatsky S., Ramsey-Goldman R., Gordon C., et al. Prostate cancer in systemic lupus erythematosus. Int J Cancer 2011, 129(12):2966-2969.
13. Green J.A., Dawson A.A., Walker W. Systemic lupus erythematosus and lymphoma. Lancet 1978, 312(8093):753-756.
14. Bernatsky S., Boivin J.F., Joseph L., et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005, 52(5):1481-1490.
15. Bernatsky S., Boivin J.F., Joseph L., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54(8):2550-2557.
16. Bernatsky S., Ramsey-Goldman R., Rajan R., et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005, 64(10):1507-1509.
17. Lu M., Bernatsky S., Ramsey-Goldman R., et al. Non-lymphoma hematological malignancies in systemic lupus erythematosus. Oncology 2013, 85(4):235-240.
18. Ali Y.M., Urowitz M.B., Ibanez D., et al. Monoclonal gammopathy in systemic lupus erythematosus. Lupus 2007, 16(6):426-429.
19. Ott G., Rosenwald A. Molecular pathogenesis of follicular lymphoma. Haematologica 2008, 93(12):1773-1776.
20. Demeter J., Messer G., Ramisch S., et al. Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther 1996, 2(4):239-242.
21. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006, 54(3):692-701.
22. Standish L.J., Sweet E.S., Novack J., et al. Breast cancer and the immune system. JSoc Integr Oncol 2008, 6(4):158-168.
23. Haabeth O.A., Lorvik K.B., Hammarstrom C., et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nature Commun 2011, 2:240.
24. Bernatsky S., Ramsey-Goldman R., Joseph L., et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis 2014, 73(1):138-142.
25. Koyama T., Tsukamoto H., Miyagi Y., et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64(7):1065-1067.
26. He B., Chadburn A., Jou E., et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. JImmunol 2004, 172(5):3268-3279.
27. James J.A., Kaufman K.M., Farris A.D., et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. JClin Invest 1997, 100(12):3019-3026.
28. Moon U.Y., Park S.J., Oh S.T., et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 2004, 6(4):R295-R302.
29. James J.A., Neas B.R., Moser K.L., et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001, 44(5):1122-1126.
30. Draborg A.H., Duus K., Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol 2013, 2013:535738.
31. Pattle S.B., Farrell P.J. The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 2006, 6(11):1193-1205.
32. Gulley M.L., Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010, 23(2):350-366.
33. Saha A., Robertson E.S. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res 2011, 17(10):3056-3063.
34. Lu M.M., Ye Q.L., Feng C.C., et al. Association of FAS gene polymorphisms with systemic lupus erythematosus: a case-control study and meta-analysis. Exp Ther Med 2012, 4(3):497-502.
35. Shi X., Xie C., Kreska D., et al. Genetic dissection of SLE: SLE1 and FAS impact alternate pathways leading to lymphoproliferative autoimmunity. JExp Med 2002, 196(3):281-292.
36. Pettersson T., Pukkala E., Teppo L., et al. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992, 51(4):437-439.
37. Moss K.E., Ioannou Y., Sultan S.M., et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis 2002, 61(5):409-413.
38. Cibere J., Sibley J., Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001, 10(6):394-400.
39. Lofstrom B., Backlin C., Sundstrom C., et al. Acloser look at non-Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis 2007, 66(12):1627-1632.
40. Bin J., Bernatsky S., Gordon C., et al. Lung cancer in systemic lupus erythematosus. Lung Cancer 2007, 56(3):303-306.
41. Hubbard R., Venn A., Lewis S., et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000, 161(1):5-8.
42. Ekblom-Kullberg S., Kautiainen H., Alha P., et al. Smoking and the risk of systemic lupus erythematosus. Clin Rheumatol 2013, 32(8):1219-1222.
43. Bernatsky S., Joseph L., Boivin J.F., et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008, 67(1):74-79.
44. Ramsey-Goldman R., Mattai S.A., Schilling E., et al. Increased risk of malignancy in patients with systemic lupus erythematosus. JInvestig Med 1998, 46(5):217-222.
45. Santana I.U., Gomes Ado N., Lyrio L.D., et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol 2011, 30(5):665-672.
46. Nath R., Mant C., Luxton J., et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007, 57(4):619-625.
47. Lee Y.H., Choe J.Y., Park S.H., et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. JKorean Med Sci 2010, 25(10):1431-1437.
48. Bernatsky S., Ramsey-Goldman R., Gordon C., et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford) 2004, 43(11):1386-1389.
49. Klumb E.M., Araujo M.L., Jesus G.R., et al. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression?. JClin Rheumatol 2010, 16(4):153-157.
50. Tam L.S., Chan A.Y., Chan P.K., et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004, 50(11):3619-3625.
51. Dreyer L., Faurschou M., Mogensen M., et al. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 2011, 63(10):3032-3037.
52. Tam L.S., Chan P.K., Ho S.C., et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study. JRheumatol 2010, 37(2):330-340.
53. Bernatsky S.R., Cooper G.S., Mill C., et al. Cancer screening in patients with systemic lupus erythematosus. JRheumatol 2006, 33(1):45-49.
54. Chang S.L., Hsu H.T., Weng S.F., et al. Impact of head and neck malignancies on risk factors and survival in systemic lupus erythematosus. Acta Otolaryngol 2013, 133(10):1088-1095.
55. Chen Y.J., Chang Y.T., Wang C.B., et al. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med 2010, 123(12):1150.e1-1150.e6.
56. Koslabova E., Hamsikova E., Salakova M., et al. Markers of HPV infection and survival in patients with head and neck tumors. Int J Cancer 2013, 133(8):1832-1839.
57. Sisk E.A., Bradford C.R., Carey T.E., et al. Epstein-Barr virus detected in a head and neck squamous cell carcinoma cell line derived from an immunocompromised patient. Arch Otolaryngol Head Neck Surg 2003, 129(10):1115-1124.
58. Asten P., Barrett J., Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. JRheumatol 1999, 26(8):1705-1714.
59. Knight A., Askling J., Granath F., et al. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 2004, 63(10):1307-1311.
60. Ruiz-Irastorza G., Ugarte A., Egurbide M.V., et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis 2007, 66(6):815-817.
61. Amaravadi R.K. Autophagy-induced tumor dormancy in ovarian cancer. JClin Invest 2008, 118(12):3837-3840.
62. Rahim R., Strobl J.S. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009, 20(8):736-745.
63. Vinet E., Bernatsky S., Suissa S. Have some beneficial effects of hydroxychloroquine been overestimated? Potential biases in observational studies of drug effects: comment on the article by Pons-Estel etal. Arthritis Rheum 2009, 61(11):1614-1615. [author reply: 1615-6].
64. Bernatsky S., Clarke A., Suissa S. Antimalarial drugs and malignancy: no evidence of a protective effect in rheumatoid arthritis. Ann Rheum Dis 2008, 67(2):277-278.
65. Akhmedkhanov A., Toniolo P., Zeleniuch-Jacquotte A., et al. Aspirin and lung cancer in women. Br J Cancer 2002, 87(1):49-53.
66. Moran E.M. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. JEnviron Pathol Toxicol Oncol 2002, 21(2):193-201.
67. Bernatsky S., Easton D.F., Dunning A., et al. Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues. Lupus 2012, 21(8):896-899.
68. Hansen J.E., Chan G., Liu Y., et al. Targeting cancer with a lupus autoantibody. Sci Transl Med 2012, 4(157):157ra142.
69. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997, 349(9064):1505-1510.
70. Tessier Cloutier B., Clarke A.E., Ramsey-Goldman R., et al. Breast cancer in systemic lupus erythematosus. Oncology 2013, 85(2):117-121.
71. Bates G.J., Fox S.B., Han C., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. JClin Oncol 2006, 24(34):5373-5380.